BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20590553)

  • 1. Pharmacokinetic study to optimize the intravesical administration of gemcitabine.
    Gontero P; Cattel L; Paone TC; Milla P; Berta G; Fiorito C; Carbone F; Medana C; Tizzani A
    BJU Int; 2010 Dec; 106(11):1652-6. PubMed ID: 20590553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
    Gamblin TC; Egorin MJ; Zuhowski EG; Lagattuta TF; Herscher LL; Russo A; Libutti SK; Alexander HR; Dedrick RL; Bartlett DL
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):647-53. PubMed ID: 18040687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer.
    Maffezzini M; Campodonico F; Puntoni M; Martelli A; Mattioli F
    Urology; 2009 Nov; 74(5):1078-83. PubMed ID: 19773039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer.
    Palou J; Carcas A; Segarra J; Duque B; Salvador J; Garcia-Ribas I; Villavicencio H
    J Urol; 2004 Aug; 172(2):485-8. PubMed ID: 15247710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.
    Beumer JH; Eiseman JL; Parise RA; Joseph E; Covey JM; Egorin MJ
    Clin Cancer Res; 2008 Jun; 14(11):3529-35. PubMed ID: 18519786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector.
    Lin NM; Zeng S; Ma SL; Fan Y; Zhong HJ; Fang L
    Acta Pharmacol Sin; 2004 Dec; 25(12):1584-9. PubMed ID: 15569401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical gemcitabine: a phase 1 and pharmacokinetic study.
    Witjes JA; van der Heijden AG; Vriesema JL; Peters GJ; Laan A; Schalken JA
    Eur Urol; 2004 Feb; 45(2):182-6. PubMed ID: 14734004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer.
    Campodonico F; Mattioli F; Manfredi V; Capponi G; Pasquini P; Martelli A; Maffezzini M
    Anticancer Res; 2007; 27(2):1179-83. PubMed ID: 17465260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
    Marangon E; Sala F; Caffo O; Galligioni E; D'Incalci M; Zucchetti M
    J Mass Spectrom; 2008 Feb; 43(2):216-23. PubMed ID: 17941128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.
    Laufer M; Ramalingam S; Schoenberg MP; Haisfield-Wolf ME; Zuhowski EG; Trueheart IN; Eisenberger MA; Nativ O; Egorin MJ
    J Clin Oncol; 2003 Feb; 21(4):697-703. PubMed ID: 12586808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy.
    Bassi P; De Marco V; Tavolini IM; Longo F; Pinto F; Zucchetti M; Crucitta E; Marini L; Dal Moro F
    Urol Int; 2005; 75(4):309-13. PubMed ID: 16327296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous determination of gemcitabine and its metabolite in human plasma by high-performance liquid chromatography.
    Yilmaz B; Kadioğlu YY; Aksoy Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jul; 791(1-2):103-9. PubMed ID: 12798170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
    Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry.
    Xu Y; Keith B; Grem JL
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Apr; 802(2):263-70. PubMed ID: 15018786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation.
    De Berardinis E; Antonini G; Peters GJ; Loves WJ; Van der Born K; Codacci-Pisanelli G; Di Silverio F
    BJU Int; 2004 Mar; 93(4):491-4. PubMed ID: 15008715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates.
    Kerr JZ; Berg SL; Dauser R; Nuchtern J; Egorin MJ; McGuffey L; Aleksic A; Blaney S
    Cancer Chemother Pharmacol; 2001 May; 47(5):411-4. PubMed ID: 11391856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
    Delauter BJ; Ramanathan RK; Egorin MJ; Stover LL; Zuhowski EG; Plunkett W; Zamboni WC
    Pharmacotherapy; 2000 Oct; 20(10):1204-7. PubMed ID: 11034044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
    Veltkamp SA; Jansen RS; Callies S; Pluim D; Visseren-Grul CM; Rosing H; Kloeker-Rhoades S; Andre VA; Beijnen JH; Slapak CA; Schellens JH
    Clin Cancer Res; 2008 Jun; 14(11):3477-86. PubMed ID: 18519780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study.
    Mattioli F; Curotto A; Manfredi V; Gosmar M; Garbero C; Ambruosi C; Carmignani G; Martelli A
    Anticancer Res; 2005; 25(3c):2493-6. PubMed ID: 16080482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.